Anavex Life Sciences Corp. (AVXL) Holdings Reduced by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC reduced its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 23.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 96,976 shares of the biotechnology company’s stock after selling 29,562 shares during the period. TIAA CREF Investment Management LLC owned about 0.23% of Anavex Life Sciences Corp. worth $516,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new stake in Anavex Life Sciences Corp. in the 1st quarter worth approximately $105,000. American International Group Inc. grew its stake in Anavex Life Sciences Corp. by 7.1% in the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 1,329 shares during the period. State of Wisconsin Investment Board purchased a new stake in Anavex Life Sciences Corp. in the 2nd quarter worth approximately $151,000. Alliancebernstein L.P. purchased a new stake in Anavex Life Sciences Corp. in the 2nd quarter worth approximately $158,000. Finally, Marshall Wace North America L.P. purchased a new stake in Anavex Life Sciences Corp. in the 2nd quarter worth approximately $176,000. 24.47% of the stock is owned by hedge funds and other institutional investors.

Several analysts have commented on AVXL shares. Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, September 18th. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research note on Monday, October 30th. ValuEngine raised shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, August 9th.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at $4.08 on Friday. Anavex Life Sciences Corp. has a 12 month low of $3.17 and a 12 month high of $6.64.

COPYRIGHT VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Holdings Reduced by TIAA CREF Investment Management LLC” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://sportsperspectives.com/2017/11/19/anavex-life-sciences-corp-avxl-holdings-reduced-by-tiaa-cref-investment-management-llc.html.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL).

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply